Want to see AU:PIQ full AI Analyst Report?
Proteomics International Laboratories Ltd. (PIQ) AI Stock Analysis
Top Page
Proteomics International Laboratories Ltd.
(ASX:PIQ)
The score is primarily weighed down by weak financial performance—sharp revenue decline, persistent losses, and ongoing negative operating/free cash flow—despite the benefit of low leverage on the balance sheet. Technical indicators are mixed (some near-term stabilization but a weak longer-term trend), and valuation is constrained by negative earnings and no dividend yield data.
Proteomics International Laboratories Ltd. (PIQ) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 19.84M
- Dividend Yield
- ―
- Average Volume (3M)
- 101.27K
- Price to Earnings (P/E)
- -2.1
- Beta (1Y)
- 1.23
- Revenue Growth
- -23.71%
- EPS Growth
- -16.02%
- Country
- Australia
- Employees
- 161
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Proteomics International Laboratories Ltd. Business Overview & Revenue Model
Company Description
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict...
How the Company Makes Money
null
Proteomics International Laboratories Ltd. Financial Statement Overview
Summary
Overall financials are weak. The income statement shows sharply deteriorating performance with a ~42% YoY revenue decline in 2026 and deepening losses (including negative gross profit), and cash flow remains consistently negative with worsening free cash flow in 2026—indicating persistent cash burn. The main offset is a relatively conservatively levered balance sheet with low debt-to-equity, though equity erosion and negative ROE remain concerns.
Income Statement
12Very NegativeBalance Sheet
63PositiveCash Flow
18Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 278.01K | 278.01K | 960.39K | 892.14K | 730.34K | 1.49M |
| Gross Profit | -9.07M | -9.07M | 960.39K | -1.12M | -1.62M | -568.62K |
| EBITDA | -11.08M | -11.08M | -10.00M | -8.40M | -7.55M | -4.56M |
| Net Income | -8.56M | -8.56M | -8.11M | -6.38M | -6.23M | -4.97M |
Balance Sheet | ||||||
| Total Assets | 8.88M | 8.88M | 14.78M | 10.88M | 10.08M | 5.40M |
| Cash, Cash Equivalents and Short-Term Investments | 3.50M | 3.50M | 11.04M | 6.64M | 6.03M | 2.11M |
| Total Debt | 331.13K | 331.13K | 277.74K | 316.39K | 64.09K | 0 |
| Total Liabilities | 3.33M | 3.33M | 1.81M | 1.63M | 1.75M | 2.00M |
| Stockholders Equity | 5.81M | 5.81M | 13.17M | 9.41M | 8.38M | 3.39M |
Cash Flow | ||||||
| Free Cash Flow | -7.88M | -7.88M | -6.63M | -6.00M | -6.91M | -3.67M |
| Operating Cash Flow | -5.87M | -5.87M | -6.60M | -5.59M | -5.69M | -3.54M |
| Investing Cash Flow | -2.01M | -2.01M | -29.65K | -388.02K | -1.17M | -129.46K |
| Financing Cash Flow | 345.13K | 345.13K | 11.03M | 6.59M | 10.77M | 176.10K |
Proteomics International Laboratories Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PIQ, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.13, and below the 200-day MA of 0.22, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 47.39 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PIQ.
Proteomics International Laboratories Ltd. Peers Comparison
Overall Rating
AU:TLX53Neutral- AU:PIQ46Neutral
AU:RAD42Neutral
AU:VBS42Neutral
AU:CU640Underperform
AU:ADO38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:TLX | 53Neutral | AUD 4.47B | 96.62 | 7.24% | ― | 26.66% | 179.32% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:PIQ | 46Neutral | AUD 19.84M | -2.06 | -129.15% | ― | -23.71% | -16.02% |
| AU:RAD | 42Neutral | AUD 23.55M | -0.32 | -144.24% | ― | -23.82% | 12.36% |
| AU:VBS | 42Neutral | AUD 4.66M | 2.60 | 206.11% | ― | ― | ― |
| AU:CU6 | 40Underperform | AUD 585.74M | -5.41 | -51.15% | ― | ― | -44.83% |
| AU:ADO | 38Underperform | AUD 52.24M | -11.43 | -77.75% | ― | -51.74% | 24.00% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:PIQ | Proteomics International Laboratories Ltd. | 0.12 | -0.20 | -62.50% | |
| AU:TLX | Telix Pharmaceuticals Ltd. | 13.13 | -2.68 | -16.95% | |
| AU:VBS | Vectus Biosystems Limited | 0.07 | -0.07 | -48.28% | |
| AU:ADO | AnteoTech Ltd | 0.02 | -0.00 | -5.88% | |
| AU:CU6 | Clarity Pharmaceuticals Ltd. | 1.57 | -3.25 | -67.43% | |
| AU:RAD | Radiopharm Theranostics Limited | 0.01 | -0.02 | -60.00% |
Proteomics International Laboratories Ltd. Corporate Events
Proteomics International to launch national rollout of Promarker blood tests via Healius
Proteomics International Laboratories is accelerating the commercialisation of its Promarker diagnostic blood tests through a national partnership with pathology provider Healius, using its accredited lab and Healius’ national collection networ...
Proteomics International sets 2026 AGM to vote on director pay and extra placement capacity
Proteomics International Laboratories Ltd has called its annual general meeting for 20 November 2026 at the Harry Perkins Institute in Nedlands, Western Australia. Shareholders will receive the financial and remuneration reports for the year ended 30...
Proteomics International Secures $2 Million R&D Tax Incentive to Support Precision Diagnostics
Proteomics International Laboratories has boosted its cash reserves with a $2.0 million research and development tax incentive received for the 2025-26 financial year. The rebate reflects $4.6 million in eligible R&D expenditure by the company an...
Proteomics International Highlights Investment Summit Disclosure Cautions
Proteomics International Laboratories Ltd has released a presentation for the Ignite Investment Summit outlining its disciplined approach to commercial success. The company emphasizes that the material is informational only and should not be used as...
Proteomics International validates Promarker Endo blood test for endometriosis
Proteomics International Laboratories has completed refinement and independent validation of its Promarker Endo blood test, a mass spectrometry-based assay designed to assess the risk of endometriosis using protein biomarkers and clinical factors. Va...
Proteomics International Sets AGM Date and Director Nomination Deadline
Proteomics International Laboratories Ltd has scheduled its Annual General Meeting for 20 November 2026, to be held at the Harry Perkins Institute in Perth at 9:30am AWST. The company has set 2 October 2026 as the closing date for receiving nominatio...
Proteomics International outlines strategy and cautions on forward-looking projections
Proteomics International Laboratories has released an investor presentation outlining its latest corporate information and strategic positioning to the market. The document emphasises that any expectations or projections about future financial perfor...
Proteomics International begins commercial rollout of Promarker tests with Healius
Proteomics International Laboratories has begun a controlled market release of its Promarker D and Promarker Eso blood tests in Western Australia and the Northern Territory under an exclusive national pathology distribution agreement with Healius. Th...
Proteomics International Lifts Revenue but Posts Wider Annual Loss
Proteomics International Laboratories Ltd reported a 3.0% increase in revenues from ordinary activities and other income to $3.61 million for the year ended 30 June 2026, but the company’s net loss widened 5.5% to $8.56 million. No dividends we...
Proteomics International Outlines 2026 Governance Compliance and Board Structure
Proteomics International Laboratories Ltd has released its Corporate Governance Statement for the financial year ended 30 June 2026, outlining compliance with the ASX Corporate Governance Council’s fourth edition principles and recommendations....
Proteomics International Wins Australian Patent for Endometriosis Blood Test
Proteomics International has received a notice of acceptance from IP Australia for a patent covering its PromarkerEndo blood test, an innovative diagnostic for endometriosis that uses specific protein biomarkers to aid diagnosis and guide treatment s...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 14, 2026